N/A N=50 Randomized Triple-blind Treatment

B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading

Fluid Over-load

Bottom Line

View on ClinicalTrials.gov: NCT01584518 ↗

Enrolled (actual)

Serious AEs

8.0%

Results posted

Mar 2016

Primary outcome: Primary: Length of Stay — 4; 6 days

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Furosemide (Drug)
Age: Adult, Older Adult · 19+ yrs
Sex: All
Sponsor: Creighton University
Primary completion: Jun 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Length of Stay	4; 6	—

Summary

The long-range goal of this proposal is to decrease morbidity and mortality related to pulmonary edema and congestive heart failure (CHF) in post-operative patients. The short-range goal is to determine a mechanistic endpoint when therapy for impending heart failure can be initiated and terminated based on B-type natriuretic peptide (BNP) levels. The investigators propose to utilize changing levels of BNP as a surrogate marker for CHF.

Eligibility Criteria

Inclusion Criteria

General Surgery patients with history of coronary artery disease, congestive heart failure, pulmonary hypertension
Cardiac surgery patients undergoing CABG (coronary artery bypass grafting) and valve replacements

Exclusion Criteria

Recent myocardial infarction (within 3 months).
ASA class 4 and more.
Emergency surgeries.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01584518). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.